With over 3 600 Western Cape users, lenacapavir is “cool”
From counselling about small nodules to overcoming people’s fears of needles, Biénne Huisman takes the pulse of a new HIV prevention injection’s rollout in the Western Cape.
Some pharmacists can now apply for permits to provide HIV prevention pills without a doctor’s script
Ten months after an enabling court judgment, some pharmacists in South Africa can finally start applying for permits that allows them to dispense HIV prevention pills without a script from a doctor. Catherine Tomlinson reports.
Positive interim findings on new once-weekly HIV treatment pill
A new antiretroviral combination pill that is taken only once a week appears to work as well as daily pills at treating HIV. This is according to interim study findings to be presented next week at the AIDS 2026 conference in Rio de Janeiro, Brazil.
Young people gave their time, their bodies, and their trust to help unlock breakthrough HIV prevention jab
As South Africa marks 50 years since the June 1976 youth uprising for a dream of freedom, a new generation of young people dreaming of an HIV-free future gave their time, trust, and participation to help deliver a breakthrough new HIV prevention product that was launched this June, writes Ntando Yola.
Did US aid cuts break precisely the things we need most for the lenacapavir rollout?
With a new six-monthly injection, South Africa last week launched the most promising new HIV prevention tool in years, but much of the infrastructure that made HIV prevention services accessible to high-risk groups has been dismantled over the last year. Amy Green asks whether we can successfully deliver this breakthrough technology without the trusted pathways that were decimated by cuts to aid from the United States.
In The Spotlight | All you need to know about the jab that could dramatically reduce new HIV infections in SA
On June 5 2026, an HIV prevention injection will for the first time become available at some of South Africa’s public sector clinics. In this Spotlight special briefing, Marcus Low and Elri Voigt pull together all you need to know about this “breakthrough” jab.
Spotlight’s top 9 health stories to watch in 2026
From the limited rollout of a new HIV prevention jab to developments with new weight loss medicines, to high-stakes court cases relating to National Health Insurance (NHI), 2026 is set to be another tumultuous year in healthcare. Here are nine stories that Spotlight will keep a close eye on.
Health in 2025: The year in fewer than 1 000 words
The year’s biggest health story by far has been the cuts to US aid for health and US support for health research. But it’s also been a year of important HIV prevention developments, NHI court cases, ongoing crises in some of our provincial health departments, and some first steps toward accountability for the corruption at Tembisa Hospital.
Breakthrough HIV prevention jab given green light in SA
An HIV prevention jab that provides six months of protection at a time was given the green light by South Africa’s medicines regulator. The approval helps to clear the way for a limited public sector rollout of the “game-changing” shot set to start in April 2026.
A new HIV prevention jab could end AIDS – unless secrecy and greed get in the way
A new HIV prevention jab has the potential to bring an end to the AIDS epidemic. But a lack of ambition and unjustifiable secrecy over pricing is holding it back, argue three leading health activists.
IAS2025: Findings give hope for monthly HIV prevention pill
An HIV prevention pill that could provide a month of protection per tablet has been given the green light to proceed to pivotal trials to test its efficacy. Elri Voigt reports on new findings on the pill that were presented at the International AIDS Conference.
Why some babies in South Africa are still getting HIV
Over the last two decades, South Africa made massive progress in reducing transmission of HIV from mothers to their babies. Even so, about 7 000 babies still contract the virus every year. Experts put this down to having the right puzzle pieces for prevention but failing to integrate them optimally. Elna Schütz reports.
